Announcement on Severe Abnormal Fluctuations in Stock Trading and Risk Warning
Securities code: 600664 Securities abbreviation: Harbin Pharmaceutical Group Co., Ltd. Number: 2026-034 Harbin Pharmaceutical Group Co., Ltd.
Announcement of serious abnormal fluctuations in stock trading and risk warning
The company's board of directors and all directors guarantee that there are no false records, misleading statements or major omissions in the announcement content, and assume legal responsibility for the authenticity, accuracy and completeness of its content.
Important content reminder:
As of the close of trading on July 23, 2026, the cumulative daily closing price increase deviation of Harbin Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") stock for 10 consecutive trading days has reached 100%. According to the relevant provisions of the "Shanghai Stock Exchange Trading Rules", it is a case of serious abnormal fluctuations in stock trading.
After the company’s self-examination and verification with the company’s controlling shareholder Harbin Pharmaceutical Group Co., Ltd. (hereinafter referred to as the “controlling shareholder”), as of the disclosure date of this announcement, the company does not have any major information that should be disclosed but has not been disclosed.
The company’s stock price has increased by 96.08% cumulatively since July 10, 2026. It hit the abnormal stock trading volatility indicator twice in a row on July 13 and July 16, and hit the serious abnormal volatility indicator on July 23; the company’s stock turnover rates in the past five trading days were 34.70%, 29.46%, 28.85%, 25.36%, respectively. 21.44%, which is significantly larger than in the past, and stock trading volume has increased significantly; according to data from the official website of China Securities Index Co., Ltd., as of the close of July 22, the company’s static price-to-earnings ratio for the industry classification "Pharmaceutical Manufacturing (C27)" of the China Association of Public Companies (C27) was 28.13 times, and the company’s static price-to-earnings ratio was 41.65 times, significantly higher than the level of listed companies in the same industry. The company's stock price has increased significantly in the short term, significantly higher than the industry and Shanghai Composite Index increases over the same period. The current transaction risk is relatively high, and there is a risk of rapid decline at any time. The company solemnly reminds investors to carefully evaluate transaction risks and make investment decisions rationally.
1. Specific circumstances of serious and abnormal stock trading fluctuations
The cumulative deviation of the daily closing price increase of the company's stock from July 10 to July 23, 2026, for 10 consecutive trading days reached 100%. According to the relevant provisions of the "Shanghai Stock Exchange Trading Rules", it is a case of serious abnormal fluctuations in stock trading.
2. Relevant situations that the company pays attention to and verifies
(1) Production and operation conditions
After the company's self-examination, the company's current production and operation conditions are normal, there have been no major changes in the internal and external operating environment, there are no major events that affect the company's stock trading price, and there is no major information that should be disclosed but has not been disclosed.
(2) Major events
After inquiries from the company's controlling shareholders, there is no major information that should be disclosed but has not yet been disclosed by the company's controlling shareholders and its shareholders, including but not limited to major asset reorganizations, share issuances, major transactions, business reorganizations, share repurchases, equity incentives, bankruptcy reorganization, major business cooperation, introduction of strategic investors and other major events.
(3) Media reports, market rumors, and hot concepts
After the company's self-examination, no media reports or market rumors were found that had a major impact on the company's stock trading price and required a clarification and response from the company.
(4) Other price-sensitive information
After verification, the company found no other major events that may have a greater impact on the company's stock price. The company's controlling shareholders, directors, and senior managers did not buy or sell the company's stocks during the company's serious and abnormal stock trading period.
3. Related risk warnings
(1) Market transaction risks
Since July 10, 2026, the closing price of the company's stock price has increased by a cumulative 96.08%. On July 13 and July 16, it hit the abnormal stock trading volatility indicator twice in a row, and on July 23, it hit the serious abnormal volatility indicator. The company's stock price has increased significantly in the short term, and there may be a risk of a rapid fall in stock price in the future. Investors are advised to pay attention to investment risks.
The turnover rates of the company's stocks in the past five trading days were 34.70%, 29.46%, 28.85%, 25.36%, and 21.44% respectively, which was significantly higher than in the past, and the stock trading volume was significantly increased; according to data from the official website of China Securities Index Co., Ltd., as of the close of July 22, the static price-to-earnings ratio of the industry classification "Pharmaceutical Manufacturing (C27)" of the China Association of Public Companies to which the company belongs was 28.13. times, the company's static price-to-earnings ratio is 41.65 times, significantly higher than the level of listed companies in the same industry. The company solemnly reminds investors to carefully evaluate transaction risks and make investment decisions rationally.
(2) Production and operation risks
On July 10, 2026, the company disclosed the company's 2026 half-year performance increase announcement. It is expected that the net profit attributable to the owners of the parent company in the 2026 half-year will be 380.2169 million yuan to 437.2495 million yuan, a year-on-year increase of 46.40% to 68.36%. It is expected that the net profit attributable to the owners of the parent company after deducting non-recurring gains and losses will be 329.4414 million yuan to 378.8576 million yuan in the first half of 2026, a year-on-year increase of 34.93% to 55.17%.
For details, please refer to the "Harbin Pharmaceutical Group Co., Ltd. 2026 Semi-annual Performance Advance Announcement" (announcement number: 2026-028) disclosed by the company on the Shanghai Stock Exchange website (www.sse.com.cn).
As of the disclosure date of this announcement, the company has no production and operation risks that would affect serious and abnormal fluctuations in stock trading prices, and there is no need to supplement or correct the above performance forecast.
(3) Other risks
After verification, the company found no other risks that may have a greater impact on the stock price.
We hereby solemnly remind investors that "Shanghai Securities News" and "Securities Times" are the company's designated information disclosure newspapers, and the Shanghai Stock Exchange website is the company's designated information disclosure website. All relevant company information is subject to the company's announcements published in the above designated media. Investors are kindly requested to invest rationally and pay attention to risks.
4. Statement of the Board of Directors and Commitments of Related Parties
The board of directors of the company confirmed that according to the relevant provisions of the "Stock Listing Rules of the Shanghai Stock Exchange" and other relevant regulations, the company has no matters that should be disclosed but has not been disclosed, or there are no plans, negotiations, intentions, agreements, etc. related to the matter. The board of directors has not been informed that the company has information that should be disclosed in accordance with the "Stock Listing Rules of the Shanghai Stock Exchange" and other relevant regulations but has not been disclosed, which may have a greater impact on the trading price of the company's stocks; there is no need to correct or supplement the information disclosed by the company in the previous period.
Announcement is hereby made.
Board of Directors of Harbin Pharmaceutical Group Co., Ltd.
July 24, 2026